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1. Introduction 
Cardiac allograft vasculopathy (CAV) is a unique form of accelerated atherosclerosis and 
remains the leading cause of late morbidity and mortality in heart transplant patients 
accounting for 30% mortality at 5 years (Miller et al., 1993), (Taylor et al., 2007). 
Although the pathogenesis of CAV is not fully elucidated, it seems to result from a complex 
interplay between immunologic and nonimmunologic factors, with consequent repetitive 
vascular injury and a localized sustained inflammatory response (Costanzo et al., 1998), 
(Julius et al., 2000). CAV affects large epicardial vessels and the microcirculation which 
results in a progressive luminal narrowing (Gao et al., 1990) and reduces myocardial blood 
flow (Kushwaha et al., 1998). CAV may be present in intramyocardial vessels even if 
epicardial disease is not evident (Clausell et al., 1995). Autopsy findings have demonstrated 
the presence of CAV in nearly all specimens at two years and changes are seen as early as 6 
weeks after cardiac transplant (Baldwin et al., 1987), (St. Goar et al., 1992).  
Early CAV is clinically silent, and ischemia is usually not evident until the disease is far 
advanced (Ciliberto et al., 1993), (Collings et al., 1994, (Mairesse et al., 1995), (Smart et al., 
1991), (Stark et al., 1991) and graft failure tends to develop as a late manifestation of the 
disease. Therefore, identification of the asymptomatic patient at early stages of the disease is 
an important strategy for the prevention of irreversible detrimental effects on the graft. 
2. IVUS and allograft vasculopathy 
2.1 Limitations of coronary angiogram 
Noninvasive screening tests for CAV such as the exercise electrocardiogram, thallium 
scintigraphy, and exercise radionucleotide ventriculography have shown insufficient 
sensitivity and specificity for reliable detection of CAV (Smart, 1991). Traditionally, coronary 
angiography has been used for the diagnosis of CAV and, according to the amount of stenosis 
in the most severely affected vessel, CAV is usually classified as absent (0% stenosis), mild (up 
to 30% stenosis), moderate (30–70% stenosis), or severe (>70% stenosis).  
However, coronary angiography, given that it basically provides images in the form of a 
lumenogram, has been shown to systematically underestimate the presence of coronary 
atherosclerosis in transplant recipients as validated in autopsy studies (St. Goar et al., 1992), 
(Dressler et al., 1992). No information on vessel wall structure and intimal thickening is 
provided by coronary angiography. Being a highly specific (97.8%) tool, the diffuse nature of 
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CAV limits the sensitivity of coronary angiography to 79.3% (Sharples et al., 2003), (St. Goar et 
al., 1992). As a result, one fifth of patients with CAV have false normal coronary angiography 
(Sharples et al., 2003). Moreover, the reported 50% negative predictive value (Cale et al. 2010) 
limits the clinical utility of routine angiographic surveillance for CAV in heart transplant 
recipients. Based on these limitations, at least one transplant center has abandoned coronary 
angiogram for routine monitoring of heart-transplant recipients (Clague et al., 2001).  
Intravascular ultrasound (IVUS)  is a safe and reproducible imaging technique (Batkoff et 
al., 1996) that is more sensitive than angiography and useful for the early diagnosis of CAV, 
morphometric and volumetric analysis, assessing plaque composition and vessel 
remodeling (Miller et al., 1995), (Pflugfelder et al., 1993), (St. Goar et al., 1992), (Yeung et al., 
1995). Whereas angiographic disease is present in 10% to 20% of patients at 1 year and 50% 
by 5 years after transplantation (Gao et al., 1988), (Uretsky et al., 1987) the prevalence of 
abnormal intimal thickening is seen in 50% of patients by 1 year in IVUS imaging (Gao et al., 
1988), (Tuzcu et al., 1996), (Yeung et al., 1995). Therefore, IVUS is now considered the “gold 
standard” for the evaluation of CAV (Kapadia et al., 2000).  
2.2 Lesion morphology and quantitative analysis 
IVUS reveals cross sectional coronary artery image, which in post-transplant patients typically 
have tri-laminar appearance (Figure 1) with bright inner layer (intima), an echo-fine middle 
layer (media) and a bright dense outer layer (adventitia); and allows the following 
measurements: (1) maximal intimal thickness (MIT) as the greatest distance from the intimal 
leading edge to media-adventitia border, (2) minimal intimal thickness as the shortest distance 
from the intimal leading edge to media-adventitia border, (3) minimal luminal diameter as the 
shortest distance between opposing intimal leading edges, (4) lumen area as the area within 
the boundaries of the intimal leading edge, (5) vessel area as the area within the media-
adventitia border, (6) plaque cross-sectional area as the difference between vessel and lumen 
areas, (7) plaque index as (lumen area/vessel area) X 100, and (8) eccentric index: [(maximal 
plaque thickness - minimal plaque thickness)/ maximal plaque thickness] X 100 (Figure 2). 
 
  
Adapter from Tuzcu et al., 1995 
Inset shows the three layers of the vessel wall (black arrow). The thin echogenic inner layer corresponds 
to the intima, the thin echolucent middle layer to the media, and the echogenic outer layer to the 
adventitia 
Fig. 1. Ultrasound image of a normal coronary artery  
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Adapted from Tuzcu et al., 1995 
Fig. 2. Measurements of lumen and vessel wall dimensions in an ultrasound image 
The maximal intimal thickness (MIT) assessed by 2D-IVUS is a commonly used measure to 
describe the severity of lesions and has been defined as a clinically useful surrogate for 
clinical outcome (Mehra et al., 1995a), (Rickenbacher et al., 1995a). The threshold of MIT > 
0.5 mm is usually acceptable (Kapadia et al., 2000), but this categorical classification of MIT, 
a continuous variable, into normal or abnormal is inherently arbitrary. This definition, 
however, is based on information provided by histological and ultrasound studies. In an 
autopsy study, normal intimal thickness, not including media, ranged between 0.10 and 0.30 
mm in individuals between 21 and 40 years of age (Sims et al., 2002), (Velican et al., 1985). 
Therefore, intimal thickness > 0.3 mm is considered to represent significant CAV. A 
classification of the vascular disease severity according to intimal thickness and degree of 
vessel circumference involved was proposed by the Stanford group (Table 1).  
The thickness of the media is usually about 0.02-0.23 mm and is unchanged or decreased with 
the development of CAV. Thus, the thickness of the normal intima plus media in young and 
middle age individuals ranges from 0.45 to 0.50 mm. (Sims et al., 2002), (Velican et al., 1985). 
 
 
Adapted from St. Goar, 1992 
Table 1. Ultrasound classification of CAV in cardiac transplant recipients) 
Despite this immense value of IVUS in the detection of CAV, there is controversy 
regarding the methodology and imaging protocols. Site selection and adequate sampling 
for quantitative analysis is crucial. Most studies have selectively visualized the LAD, 
making the assumption that CAV occurs uniformly throughout the coronary tree. It has 
been demonstrated, that multi-vessel imaging is definitely more sensitive in detecting 
transplant vasculopathy lesions compared to single-vessel imaging (Kapadia, 2000), and 
sampling of a single coronary artery for imaging may not be sufficient to adequately 
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assess the prevalence of CAV. However, multi-vessel imaging is time consuming, adds to 
the cost of the procedure and, although procedural complications other than occasional 
spasm resolved with intracoronary nitroglycerin did not occur, the long-term safety of the 
multi-vessel imaging remains unknown. Thus, the limitations of single vessel imaging 
should be weighed against the potential benefits from adequate sampling of multi-vessel 
imaging.  
2.3 Three-dimensional reconstruction (3D-IVUS) 
2D-IVUS has limitation in spatial registration and the inability to assess the full extent of 
vascular disease (Tuzcu, 2005) which reduces its sensitivity to detect the changes of 
atherosclerotic burden in CAV. Three-dimensional (3D-IVUS) reconstruction allows rapid 
and accurate measurement of volume and plaque dimensions with full extent of 
atherosclerotic pathology. Automated pullback with a known pullback speed is necessary. 
The vessel, lumen and plaque volume can be calculated using the Simpson rule for images 
that are 1 mm apart. Since the histology literature does not commonly depend on volumetric 
indices, currently, there is no well-defined threshold for these measurements and the 
information is not readily obtainable. Because of its superior reproducibility, however, 3D-
IVUS may be used to assess the progression of coronary artery disease and allow for more 
accurate evaluation of interventions aimed at preventing or attenuating coronary artery 
disease (Bae et al., 2006), (White et al., 2003). 
2.4 Virtual Histology Intravascular Ultrasound (VH-IVUS) 
Grayscale IVUS is able to visualize coronary atherosclerosis in vivo and allows rapid and 
accurate assessment of plaque area and distribution, lesion length, and coronary 
remodelling (Bae et al., 2006), (Kapadia et al., 2000), (White et al., 2003), but has a significant 
limitation in the evaluation of atherosclerotic plaque composition.  
VH-IVUS is a novel technology to characterize the different types of plaque morphology in 
vivo which based on the spectral analysis of the radiofrequency ultrasound signals in a 
frequency domain (Nair et al., 2002), (Nasu et al., 2006), (Rodriguez-Granillo et al., 2005). It 
displays the reconstructed color coded tissue map of plaque composition overlaid on a grey-
scale image and groups plaque components into 4 basic tissue types: fibrous tissue (green), 
fibro-fatty tissue (light green), necrotic core (red), and dense calcium (white). (Figure 3) This 
approach has not been validated with histological techniques in heart transplant patients, 
however in the non-transplant population the overall predictive accuracies were 90.4% for 
fibrous tissue, 92.8% for fibrolipidic, 89.5% necrotic core, and 90.9% for dense calcium (Nair 
et al, 2001), (Nair et al, 2002), (Nasu et al, 2006). In native coronaries morphological 
composition of atherosclerotic plaque is a useful determinant of the plaque vulnerability 
(Ehara et al., 2004), (Naghavi et al., 2003), (Valgimigli et al., 2007), and identified plaques 
with a high-risk of future clinical events (Bae et al., 2008), (Kawaguchi et al., 2007), 
(Kawamoto et al., 2007). After heart transplantation, simultaneous assessment of virtual 
histology with IVUS provides detailed information about plaque morphology and 
composition, may improve the risk stratification of heart transplant recipients (Konig et al., 
2008) and add important information in the clinical evaluation of heart transplant recipients 
(Raichlin et al., 2009).  
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(Left) Gray scale IVUS cross-section imaging shows concentric plaque: a (PV/SL) of 6.79 and a PI of 32% 
was calculated  
(Right) The corresponding VH-IVUS image depicts specific color-coded plaque components and 
demonstrates fibrous plaque of 47%, fibrofatty plaque of 20%, dense calcium of 14%, and necrotic core 
of 27%.PV/SL, plaque volume normalized for segment length; PI, plaque index 
Adapted from Raichlin et al., 2007b 
Fig. 3. Gray scale IVUS cross-section imaging shows concentric plaque with corresponding 
VH-IVUS image 
2.5 Impact of IVUS in understanding coronary allograft vasculopathy 
Morphologic studies performed with IVUS have led to important insights into the etiology 
and pathogenesis of CAV.  
Coronary artery vasculopathy (CAV) is a multifactorial phenomenon with variable 
morphologic features. Previous histological ex-vivo studies described two microscopic 
types of coronary allograft lesions (Johnson, 1989). One type of coronary lesion is confined 
to the proximal region of epicardial arteries and indistinguishable from typical 
atherosclerosis of native vessels. The second type is characterized by the presence of 
vasculitis, involving the entire coronary arterial system and has been suggested to 
represent the immune mediated vessel injury (Higuchi et al., 1999). The ability to 
differentiate between the existence of classic atherosclerosis and transplant-specific 
immunologically mediated CAV holds both prognostic and therapeutic values and this 
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morphologic heterogeneity has been evident in gray scale (Tuzcu et al., 1996) and VH-
IVUS study (Raichlin et al., 2009).  
Typical atherosclerosis has been detected in 56% of donor hearts despite a mean donor age 
of thirty-two years (Tuzcu et al., 1995) and IVUS studies have demonstrated that 
atherosclerotic lesions located in proximal segments, involved the bifurcation sites with 
eccentric focal plaques, appeared similar to conventional atherosclerosis, were associated 
with fibrotic and fibro-fatty tissues in VH-IVUS (Konig et al., 2008), (Raichlin et al., 2009) 
positively correlated with the donor age and probably related to donor-derived coronary 
atherosclerosis (Kapadia et al., 1998), (Tuzcu et al., 1996).  
On other hand de novo lesions assessed by IVUS were diffuse and circumferential, involved 
more commonly the mid and distal segments of the coronary arteries (Kapadia et al., 1998) 
and were associated with necrotic core and dense calcium burden ≥ 30%, which presumably 
reflects the inflammatory burden of the cardiac allograft atherosclerotic plaque (Raichlin et 
al., 2009). (Figure 4) 
Previous studies have demonstrated that early immunological events surrounding 
engraftment lead to an inflammatory process in the vascular endothelium (Brunner-La 
Rocca et al., 1998), (Caforio et al., 2004),  (Hornick et al., 1997), (Jimenez et al., 2001), (Narrod 
et al., 1989), (Opelz et al., 1997), (Vassalli et al., 2003), (Yamani et al., 2002). Although CAV 
may develop at any stage after transplantation, events during the first year, resulting most 
likely from initial and ongoing immunologically mediated injury to the vascular 
endothelium appear to be important in CAV pathogenesis (Kobashigawa et al., 2003) 
leading to more rapid progression in intimal thickening during the first year after 
transplantation (Kobashigawa et al., 1995), (Mehra et al., 1995d), (Rickenbacher et al., 1995a). 
A cross-sectional study demonstrated a mean absolute increase of 0.23 mm 10% in intimal 
thickening and intimal index respectively (Kobashigawa, 1995) during the first year of 
transplantation. After the first year, the intimal thickness and intimal area do not increase 
rapidly but new lesions continue to develop at previously normal sites (Kapadia SR et al., 
1998). This underscores the importance for continued surveillance for transplant 
vasculopathy beyond first year after transplantation. 
A relationship between immune events and an increase in systemic inflammatory markers 
following heart transplantation has been shown in several clinical studies (Eisenberg, 2000), 
(Labarrere, 2002) suggesting that chronic inflammation may be a central event in cardiac 
allograft vasculopathy. Experimental evidence demonstrated that acute cellular allograft 
rejection and CAV are closely related processes (Brunner-La Rocca et al., 1998), (Caforio et 
al., 2004), (Hornick et al., 1997), (Jimenez et al., 2001), (Narrod et al., 1989), (Opelz et al., 
1997), (Vassalli et al., 2003), (Yamani et al., 2005) and elevated systemic levels of the 
inflammatory markers were predictive not only of cardiac allograft vasculopathy but also of 
allograft failure (Eisenberg & Pethig, 2000), (Hognestad et al., 2003), (Labarrere et al., 2002), 
(Raichlin et al., 2007b). An association between early recurrent cellular rejections and an 
increase in intimal thickening (Mehra et al., 1995a) and the presence of necrotic plaque 
(Raichlin et al., 2007b) has been revealed in 2D and VH-IVUS studies. Moreover, focal 
inflammation as assessed by VH-IVUS resulted in subsequent progression of CAV. Thus, 
VH-IVUS can be used for in-vivo identification of patients with increased burden of 
“inflammatory plaque” and the predicting the progression of CAV following heart 
transplantation (Raichlin et al., 2009). (Figure 5) 
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Adapted from Raichlin et al., 2009 
Fig. 4. Grayscale intravascular ultrasound (IVUS) cross-section imaging (bottom) and 
corresponding virtual histology (VH)-IVUS images (top) from patients with VH-IVUS–
derived inflammatory plaque 
 
   
A Progression in plaque volume in VH-IVUS derived inflammatory plaque (IP) and noninflammatory 
plaque (NIP) groups 
Change in Plaque Volume (mm3/mm) IP (n=21) 2.42 ± 1.78; NIP (n=17) -0.11±1.65; p=0.01  
B Progression in plaque index in the in VH-IVUS derived inflammatory plaque (IP) and 
noninflammatory plaque (NIP) groups 
Change in Plaque Index (%): IP (n=21) 7± 9; NIP (n=17) 0.1± 8; p=0.04 
C Remodeling index in VH-IVUS derived inflammatory plaque (IP) and noninflammatory plaque (NIP) 
groups 
Remodeling Index: IP (n=21) 1.24 ± 0.44, NIP (n=17) 1.09 ± 0.36; p=0.03 
Adapted from Raichlin et al., 2009 
Fig. 5. Progression in Plaque Volume, Plaque Index, and Remodeling Index in IP and NIP 
Groups  
The natural history of donor lesions after transplantation is largely unknown. In the 2010 
ISHLT registry older donor age is an independent risk factor for early CAV (Stehlik et al., 
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1089). Several studies, however, have found no significant difference in the rate of intimal 
thickening between patients with donor hearts having pre-existing coronary artery disease 
and those without (Botas et al., 1995), (Li et al., 2006). From multiple variables only serum 
triglyceride level and pre-transplant body mass index were found to be significant predictors 
for the progression of donor atherosclerosis (Kapadia SR et al., 1998). A VH-IVUS study has 
demonstrated relatively slow progression of CAV in a group of patients with fibrous, 
presumably donor-derived plaque (Raichlin et al., 2009).(Figure 5) Several studies, however, 
have shown that the presence of donor lesions leads to the more frequent development of de 
novo transplant vasculopathy lesions (Botas et al., 1995), (Escobar et al., 1994), (Gao et al., 
1997). The impact of donor and recipient gender on transplant vasculopathy has also been 
assessed. Male recipients of a female allograft had a higher degree of vascular intimal 
hyperplasia compared with either male or female recipients of a male allograft as detected by 
IVUS imaging 1 year after heart transplantation (Mehra et al., 1994). 
Arterial remodeling has been studied in the transplant population in serial and cross-
sectional IVUS study designs. In its early stages, CAV shows no decrease in luminal 
diameter due to vascular remodeling, thus limiting the ability of angiography to detect and 
diagnose early CAV (Nissen et al., 2001). Three year serial IVUS studies have shown that the 
rate of remodeling of donor lesions is different from CAV. Furthermore, the rate of 
remodeling is different depending on the time interval from transplantation (Ziada et al., 
1997). Both compensatory local vessel enlargement (positive remodeling) and vascular 
constriction (negative remodeling) have been demonstrated and it is thought that 
inadequate compensatory enlargement probably contributes significantly to luminal 
obstruction (Pethig et al., 1998). In a study of 3D-VH-IVUS, the coronary arteries with 
“inflammatory plaque” showed positive remodeling compared to “non-inflammatory 
plaque” (Raichlin et al., 2009).(Figure 5) These data are consistent with previous findings 
from a non-transplant population, which showed that inflammation is associated with 
expansion of the internal elastic lamina and positive remodeling closely correlates with 
plaque vulnerability (Burke et al., 2004), (Rodriguez-Granillo et al., 2006).  
IVUS imaging has also have been used to evaluate the impact of non-immunological factors 
in the development of transplant vasculopathy lesions. Total cholesterol, low-density 
lipoprotein cholesterol, triglyceride levels, obesity indexes, donor age greater than 35, and 
years following cardiac transplantation were independent predictors of the severity of 
cardiac allograft vasculopathy as determined by the severity of intimal thickening (Escobar 
et al.,, 1994), (Hauptman et al., 1995), (Mehra et al., 1995), (Rickenbacher et al., 1995b), 
(Valantine et al., 1995).  
2.6 Clinical applications 
Studies performed using IVUS have shown a strong association between the severity of the 
disease and the clinical outcome. Severe intimal thickening predicted both events (death, 
MI, and re-transplantation) and survival in patients after transplantation (Mehra et al., 
1995b), (Mehra et al., 1995c) regardless of the presence of angiographic CAV (Rickenbacher 
et al., 1995b). Moreover, rapidly progressive vasculopathy, defined as an increase of ≥ 0.5 
mm in intimal thickness within the first year after transplantation, was a powerful predictor 
of all-cause mortality, nonfatal MI, and the subsequent development of angiographic 
coronary obstructions independent of other confounding variables, including rejection 
episodes, age, gender, and conventional risk factors (Kobashigawa et al., 2005), (Tuzcu et al., 
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2005). (Figure 6 and 7) Thus, the prognostic value of IVUS has significant clinical utility in 
the identification of a high-risk population and underscores the importance of serial IVUS 
examinations (Kapadia et al., 1999).  
 
 
Adapted from Tuzcu et al., 2010 
Fig. 6. Serial intravascular ultrasound examination at baseline (left side panel) and 1 year 
follow-up (right side panel) demonstrates significant plaque development at the first year. 
Transplant vasculopathy at the same site in a coronary vessel segment  
 
 
Adapted from Tuzcu et al., 2005 
Fig. 7. Kaplan-Meier all-cause mortality (left) and death and myocardial infarction (MI) 
(right) rates of patients with and without rapidly progressive transplant vasculopathy. 
Thick lines - without rapid progression; thin lines - with rapid progression 
IVUS also provides a sensitive tool to evaluate the effectiveness of different therapeutic and 
preventive modalities influencing CAV and various clinical protocols have incorporated 
IVUS findings as surrogate end-points for clinical events. Serial IVUS has been essential as a 
research tool in studies that assess emerging transplant vasculopathy therapies (Bae et al., 
2006), (Eisen et al., 2003), (Fang et al., 2002), (Mehra et al., 1995c), (Raichlin et al., 2007a). The 
effects of early use of pravastatin on CAV have been assessed by IVUS imaging in a 
randomized study (Kobashigawa, 1995). 2D-IVUS measurements at baseline and 1 year after 
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transplantation showed less increase in MIT and maximal intimal index with pravastatin 
therapy. The incidence of coronary vasculopathy as determined by angiography and at 
autopsy also was lower (Kobashigawa, 1995).  
The influence of angiotensin-converting enzyme inhibitors and calcium blockers on the 
development of CAV has also been assessed. Mehra et al., using IVUS, demonstrated that 
heart transplant recipients treated with either diltiazem or angiotensin-converting enzyme 
inhibitors, or both have significantly less intimal hyperplasia 1 year after cardiac 
transplantation than matched untreated control subjects (Mehra et al., 1995b), (Mehra et 
al., 1995c). Another IVUS study has demonstrated that a combination of a calcium channel 
blocker and an angiotensin-converting enzyme inhibitors is more effective in CAV 
prevention than the individual use of either drug alone. This effect was independent of 
mean arterial pressure, suggesting these drugs have a synergistic anti-proliferative effect 
beyond the anti-hypertensive efficacy (Erinc et al., 2005). Moreover, a 3D-IVUS study 
demonstrated that lower serum lipid levels and angiotensin-converting enzyme inhibitors 
use in patients after heart transplantation is associated with CAV plaque regression (Bae 
et al., 2006). The question of whether supplementation with antioxidant vitamins C and E 
retards the early progression of CAV has also been assessed by 2D-IVUS (Fang et al., 
2002). 
IVUS imaging has been used to evaluate the effect of immunosuppressive therapy on the 
development of CAV. A randomized, double-blind trial, comparing mycophenolate mofetil 
with azathioprine as adjuvant to cyclosporine, revealed that the change in mean MIT was 
less for the mycophenolate mofetil group than for the azathioprine group (p = 0.056) (Eisen 
et al., 2005).  
The first clinical evidence that proliferation signal inhibitors (PSIs) could limit the 
development of CAV in heart transplant recipients was provided by an international 
multicenter randomized, double-blind study (Eisen et al., 2003) comparing everolimus with 
azathioprine as adjuvant to full dose of cyclosporin in 634 de-novo heart transplant patients. 
The results of the intravascular substudy with matched analysis of baseline and 1-year 
images were available for 211 patients. The average increase in intimal thickness was 
significantly larger with azathioprine than with everolimus. The 12 months of double-blind 
period of this study were followed by 12 month of open-labeled period (Vigano et al., 2007) 
in 149 patients and showed that continued treatment with everolimus limits the progression 
of intimal thickening and lowers the incidence of allograft vasculopathy at 24 months when 
compared with azathioprine.  
Similar benefits have also been seen in patients treated with sirolimus. In an open-labeled 
study (Keogh, 2004) of 136 de-novo transplant patients randomized to sirolimus or 
azathioprine, IVUS showed that the use of sirolimus significantly reduced the progression 
in intimal and media proliferation by six months, whereas azathioprine therapy resulted 
in increased plaque volume and plaque burden over time. This effect was sustained at 
two years.  
The first evidence of using sirolimus for primary immunosuppression after heart 
transplantation demonstrated that complete CNI withdrawal and replacement with SRL 
results in attenuation of CAV progression by reducing intimal hyperplasia as evidenced by 
3D-IVUS. Treatment with azathioprine or mycophenolate mofetil did not significantly affect 
the results. A CNI-free regimen was more effective when initiated within the first two years 
following transplantation (Raichlin et al., 2007a). 
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3. Conclusion 
Coronary angiography has a high specificity of 97.8% but only moderate sensitivity of 79.3% 
in CAV detection. The intimal changes in CAV are best detected by intravascular 
ultrasound, which has become the gold standard for the early diagnosis of CAV. The 
prognostic value of IVUS has significant clinical utility in identification a high-risk 
population and underscores the importance of serial IVUS examinations during annual 
routine screening of heart transplant recipients. 3D-IVUS with simultaneous assessment of 
virtual histology may add important information in the clinical evaluation of heart 
transplant recipients. 
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